AIFarm Valuation
| AIFM Stock | USD 0 0.00 0.00% |
AIFarm seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of AIFarm from examining the firm fundamentals such as Return On Asset of -3.28, shares outstanding of 676.83 K, and EBITDA of (487.13 K) as well as evaluating its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that AIFarm's price fluctuation is very steady at this time. Calculation of the real value of AIFarm is based on 3 months time horizon. Increasing AIFarm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AIFarm pink sheet is determined by what a typical buyer is willing to pay for full or partial control of AIFarm. Since AIFarm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AIFarm Pink Sheet. However, AIFarm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.003 | Real 0.00252 | Hype 0.003 | Naive 0.003 |
The intrinsic value of AIFarm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AIFarm's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AIFarm helps investors to forecast how AIFarm pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AIFarm more accurately as focusing exclusively on AIFarm's fundamentals will not take into account other important factors: AIFarm Total Value Analysis
AIFarm is presently forecasted to have valuation of 676.83 K with market capitalization of 676.83 K, debt of 54.73 K, and cash on hands of 88.27 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the AIFarm fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
676.83 K | 676.83 K | 54.73 K | 88.27 K |
AIFarm Asset Utilization
One of the ways to look at asset utilization of AIFarm is to check how much profit was generated for every dollar of assets it reports. AIFarm shows a negative utilization of assets of -3.28 percent, losing $0.0328 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less productive with each dollar of assets it shows. Put another way, asset utilization of AIFarm shows how discouraging it operates for each dollar spent on its assets.AIFarm Ownership Allocation
AIFarm retains considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.AIFarm Profitability Analysis
Net Loss for the year was (547.09 K) with profit before overhead, payroll, taxes, and interest of 0.About AIFarm Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of AIFarm. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AIFarm based exclusively on its fundamental and basic technical indicators. By analyzing AIFarm's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of AIFarm's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of AIFarm. We calculate exposure to AIFarm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AIFarm's related companies.AIFarm, Ltd., a development stage company, develops a proprietary growing system that designs and builds custom biodomes worldwide. AIFarm, Ltd. was founded in 2012 and is based in Kowloon, Hong Kong. Aifarm is traded on OTC Exchange in the United States.
8 Steps to conduct AIFarm's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates AIFarm's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct AIFarm's valuation analysis, follow these 8 steps:- Gather financial information: Obtain AIFarm's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine AIFarm's revenue streams: Identify AIFarm's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research AIFarm's industry and market trends, including the size of the market, growth rate, and competition.
- Establish AIFarm's growth potential: Evaluate AIFarm's management, business model, and growth potential.
- Determine AIFarm's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate AIFarm's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
AIFarm Growth Indicators
Investing in growth stocks can be very risky. If the company such as AIFarm does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 676.8 K | |
| Retained Earnings | -6.2 M |
Other Information on Investing in AIFarm Pink Sheet
AIFarm financial ratios help investors to determine whether AIFarm Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AIFarm with respect to the benefits of owning AIFarm security.